

# Alejandro Berlin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3296090/publications.pdf>

Version: 2024-02-01

129  
papers

3,633  
citations

201674

27  
h-index

155660

55  
g-index

129  
all docs

129  
docs citations

129  
times ranked

6030  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , 2017, 541, 359-364.	27.8	462
2	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , 2015, 47, 736-745.	21.4	395
3	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2014, 15, 1521-1532.	10.7	291
4	An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report. <i>Lancet Oncology</i> , The, 2017, 18, e720-e730.	10.7	220
5	Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. <i>Nature Cell Biology</i> , 2021, 23, 87-98.	10.3	209
6	ONECUT2 is a driver of neuroendocrine prostate cancer. <i>Nature Communications</i> , 2019, 10, 278.	12.8	143
7	A Prostate Cancer "Nimbus" Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674.	1.9	142
8	Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 85-94.	1.6	107
9	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	1.9	93
10	Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer. <i>Nature Medicine</i> , 2021, 27, 999-1005.	30.7	78
11	Prognostic role of Ki-67 score in localized prostate cancer: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 499-506.	1.6	72
12	Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19. <i>JAMA Oncology</i> , 2021, 7, 597.	7.1	71
13	Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases. <i>JAMA Oncology</i> , 2020, 6, 567.	7.1	64
14	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021, 80, 632-640.	1.9	61
15	Mismatch repair gene expression and genetic instability in testicular germ cell tumor. <i>Cancer Biology and Therapy</i> , 2004, 3, 977-982.	3.4	50
16	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	7.1	49
17	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. <i>European Urology</i> , 2021, 80, 374-382.	1.9	49
18	Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial. <i>Journal of Neuro-Oncology</i> , 2019, 142, 565-575.	2.9	42

#	ARTICLE	IF	CITATIONS
19	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 546-555.	0.8	42
20	Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3110-3114.	1.6	41
21	Challenges and opportunities in primary CNS lymphoma: A systematic review. <i>Radiotherapy and Oncology</i> , 2017, 122, 352-361.	0.6	38
22	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017, 72, 22-31.	1.9	37
23	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 84-91.	0.8	36
24	<i>NBN</i> gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. <i>Oncotarget</i> , 2014, 5, 11081-11090.	1.8	30
25	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 38-45.	1.9	29
26	Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2016, 15, 147-155.	0.5	28
27	Outcomes following stereotactic radiosurgery for small to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose. <i>Neuro-Oncology</i> , 2019, 21, 242-251.	1.2	27
28	Virtual care models for cancer survivorship. <i>Npj Digital Medicine</i> , 2020, 3, 113.	10.9	25
29	Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. <i>Practical Radiation Oncology</i> , 2015, 5, e473-e482.	2.1	24
30	Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 93-98.	0.6	23
31	Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. <i>BJU International</i> , 2020, 125, 525-530.	2.5	21
32	Practical considerations for prostate hypofractionation in the developing world. <i>Nature Reviews Urology</i> , 2021, 18, 669-685.	3.8	20
33	Hyperbaric Oxygen for Radiation Necrosis of the Brain. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 92-99.	0.5	19
34	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, 459-465.	0.6	18
35	International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. <i>Journal of Urology</i> , 2019, 201, 284-291.	0.4	18
36	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, e216871.	7.1	18

#	ARTICLE	IF	CITATIONS
37	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Network Open, 2021, 4, e2138550.	5.9	18
38	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer and Prostatic Diseases, 2020, 23, 646-653.	3.9	17
39	Significant tumor shift in patients treated with stereotactic radiosurgery for brain metastasis. Clinical and Translational Radiation Oncology, 2017, 2, 23-28.	1.7	16
40	Evaluation of high dose volumetric CT to reduce inter-observer delineation variability and PTV margins for prostate cancer radiotherapy. Radiotherapy and Oncology, 2017, 125, 118-123.	0.6	16
41	The reality of virtual care: Implications for cancer care beyond the pandemic. Healthcare, 2020, 8, 100480.	1.3	16
42	A Phase II Study of Neoadjuvant Stereotactic Radiosurgery for Large Brain Metastases: Clinical Trial Protocol. Neurosurgery, 2020, 87, 403-407.	1.1	15
43	Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3702-3711.	6.4	15
44	Changes in apparent diffusion coefficient radiomics features during dose-painted radiotherapy and high dose rate brachytherapy for prostate cancer. Physics and Imaging in Radiation Oncology, 2019, 9, 1-6.	2.9	14
45	Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 603.e17-603.e25.	1.6	14
46	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. European Urology Oncology, 2020, , .	5.4	13
47	<sup>18</sup> F-Fluorocholine PET Whole-Body MRI in the Staging of High-Risk Prostate Cancer. American Journal of Roentgenology, 2018, 210, 635-640.	2.2	12
48	Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases. Advances in Radiation Oncology, 2020, 5, 350-357.	1.2	12
49	The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer. European Urology Focus, 2021, 7, 537-545.	3.1	12
50	Virtual care for prostate cancer survivorship: protocol for an evaluation of a nurse-led algorithm-enhanced virtual clinic implemented at five cancer centres across Canada. BMJ Open, 2021, 11, e045806.	1.9	12
51	Deep learning for whole-body medical image generation. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3817-3826.	6.4	12
52	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Network Open, 2021, 4, e2115312.	5.9	12
53	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. European Urology, 2021, 80, 142-146.	1.9	12
54	Gaps between Evidence and Practice in Postoperative Radiotherapy for Prostate Cancer: Focus on Toxicities and the Effects on Health-Related Quality of Life. Frontiers in Oncology, 2016, 6, 70.	2.8	10

#	ARTICLE	IF	CITATIONS
55	Magnetic resonance imaging-guided functional anatomy approach to prostate brachytherapy. <i>Brachytherapy</i> , 2017, 16, 698-714.	0.5	10
56	Management and Outcomes in the Oldest-Old Population with Glioblastoma. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 199-205.	0.5	10
57	Gender-based psychological and physical distress differences in patients diagnosed with non-metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2020, 38, 2547-2554.	2.2	10
58	Transitioning to a New Normal in the Post-COVID Era. <i>Current Oncology Reports</i> , 2020, 22, 73.	4.0	10
59	Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients. <i>Current Oncology</i> , 2021, 28, 549-559.	2.2	10
60	Multispecialty Enterprise Imaging Workgroup Consensus on Interactive Multimedia Reporting Current State and Road to the Future: HIMSS-SIIM Collaborative White Paper. <i>Journal of Digital Imaging</i> , 2021, 34, 495-522.	2.9	10
61	Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. <i>Radiotherapy and Oncology</i> , 2020, 149, 240-245.	0.6	10
62	Impact of <sup>18</sup> F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer. <i>Radiology</i> , 2022, 304, 600-608.	7.3	10
63	The Use of Virtual Care in Patients with Hematologic Malignancies: A Scoping Review. <i>Current Oncology</i> , 2022, 29, 892-900.	2.2	9
64	Dosimetric feasibility of ablative dose escalated focal monotherapy with MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 103-108.	0.6	8
65	The current state of randomized clinical trial evidence for prostate brachytherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 599-610.	1.6	8
66	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 61-66.	0.8	8
67	[ <sup>18</sup> F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. <i>BMJ Open</i> , 2020, 10, e035959.	1.9	8
68	Radiation Dose Rate, Biologically Effective Dose, and Tumor Characteristics on Local Control and Toxicity After Radiosurgery for Acoustic Neuromas. <i>World Neurosurgery</i> , 2021, 152, e512-e522.	1.3	8
69	Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic. <i>Canadian Urological Association Journal</i> , 2014, 8, 783.	0.6	7
70	The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. <i>Radiation Oncology</i> , 2017, 12, 50.	2.7	7
71	Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life. <i>Brachytherapy</i> , 2019, 18, 477-483.	0.5	7
72	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 88-96.	5.4	7

#	ARTICLE	IF	CITATIONS
73	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging. <i>Advances in Radiation Oncology</i> , 2021, 6, 100553.	1.2	7
74	Sexual function and rehabilitation after radiation therapy for prostate cancer: a review. <i>International Journal of Impotence Research</i> , 2021, 33, 410-417.	1.8	7
75	Creating patient-centered radiology reports to empower patients undergoing prostate magnetic resonance imaging. <i>Canadian Urological Association Journal</i> , 2020, 15, 108-113.	0.6	7
76	COVID-19 and patients with cancer: Investigating treatment impact, information sources, and COVID-19-related knowledge, attitudes, and practices. <i>Cancer</i> , 2022, 128, 746-761.	4.1	7
77	Dosimetric impact of intrafraction changes in MR-guided high-dose-rate (HDR) brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2018, 17, 59-67.	0.5	6
78	The deleterious association between proton pump inhibitors and prostate cancer-specific mortality – a population-based cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 622-629.	3.9	6
79	Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 155, 34-39.	2.0	6
80	Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trials. <i>Journal of Neuro-Oncology</i> , 2018, 136, 585-593.	2.9	5
81	Age Differences in Patient-reported Psychological and Physical Distress Symptoms in Bladder Cancer Patients – A Cross Sectional Study. <i>Urology</i> , 2019, 134, 154-162.	1.0	5
82	In Regard to Freedland et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 237-240.	0.8	4
83	The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials. <i>Journal of Neuro-Oncology</i> , 2018, 139, 195-203.	2.9	4
84	Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada. <i>Canadian Urological Association Journal</i> , 2020, 14, E588-E593.	0.6	4
85	<sup>18</sup> F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1615-1620.	5.0	4
86	Magnetic Resonance Imaging-guided Brachytherapy Re-irradiation for Isolated Local Recurrence of Soft Tissue Sarcoma. <i>Cureus</i> , 2018, 10, e2457.	0.5	4
87	An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 278-289.	0.8	4
88	Factors correlating with survival following adjuvant or definitive radiosurgery for large brain metastases. <i>Neuro-Oncology</i> , 2022, 24, 1925-1934.	1.2	4
89	Significance of treatment response when managing patients with primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 349-357.	1.3	3
90	Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 848.e1-848.e7.	1.6	3

#	ARTICLE	IF	CITATIONS
91	Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2020, 14, 404-410.	0.6	3
92	Is there an association between a history of military service and cancer diagnosis? Results from a US national-level study of self-reported outcomes. Cancer Causes and Control, 2021, 32, 47-55.	1.8	3
93	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. Canadian Urological Association Journal, 2021, 15, E545-E552.	0.6	3
94	Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 835.e1-835.e7.	1.6	3
95	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. Canadian Urological Association Journal, 2021, 16, .	0.6	3
96	Impact of high dose volumetric CT on PTV margin reduction in VMAT prostate radiotherapy. Physics in Medicine and Biology, 2019, 64, 065017.	3.0	2
97	Predictors of prostate-specific antigen testing in men aged 55 years: A cross-sectional study based on patient-reported outcomes. International Journal of Urology, 2020, 27, 711-718.	1.0	2
98	Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?. BJU International, 2021, 127, 654-664.	2.5	2
99	18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center. Current Oncology, 2021, 28, 3251-3258.	2.2	2
100	Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 5.e1-5.e13.	1.6	2
101	Case series illustrating the synergistic use of hydrogel spacer and MR-guidance to increase the radiotherapeutic index for localized prostate cancer. Technical Innovations and Patient Support in Radiation Oncology, 2019, 11, 22-25.	1.9	2
102	Time trends of drug-specific actionable adverse events among patients on androgen receptor antagonists: Implications for remote monitoring. Canadian Urological Association Journal, 2021, 16, .	0.6	2
103	TNM Staging of Prostate Cancer: Challenges in Securing a Globally Applicable Classification. European Urology, 2022, 82, e52-e53.	1.9	2
104	Prostate Cancer Genomics as a Driver of Personalized Medicine. , 2014, , 233-245.		1
105	Role of radiotherapy in the chemotherapy-containing multidisciplinary management of patients with resected pancreatic adenocarcinoma. Strahlentherapie Und Onkologie, 2015, 191, 17-25.	2.0	1
106	Liver Failure After Abdominal Irradiation: Identifying the Right Suspects. Journal of Clinical Oncology, 2016, 34, e80-e83.	1.6	1
107	Tumour-Targeted Treatment Intensification for Prostate Cancer Using Magnetic Resonance Imaging Guidance. Journal of Medical Imaging and Radiation Sciences, 2017, 48, 336-342.	0.3	1
108	Use of hydrogel spacer for improved rectal dose-sparing in patients undergoing radical radiotherapy for localized prostate cancer: First Canadian experience. Canadian Urological Association Journal, 2017, 11, 373-5.	0.6	1



#	ARTICLE	IF	CITATIONS
109	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 702-709.	0.8	1
110	Radiosurgery and risk of intracranial malignancies: more research needed. <i>Lancet Oncology</i> , The, 2019, 20, 17-18.	10.7	1
111	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. <i>European Urology Open Science</i> , 2020, 21, 1-4.	0.4	1
112	Genomic Strategies to Personalize Use of Androgen Deprivation Therapy With Radiotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 13-20.	2.0	1
113	Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease. <i>European Urology Focus</i> , 2020, 7, 797-806.	3.1	1
114	Performance stability evaluation of atlas-based machine learning radiation therapy treatment planning in prostate cancer. <i>Physics in Medicine and Biology</i> , 2021, 66, 134001.	3.0	1
115	Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. <i>Eur Urol</i> 2021;80:374-82. <i>European Urology</i> , 2021, 80, e79-e80.	1.9	1
116	Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (<sup>18</sup>F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5553-5553.	1.6	1
117	Using NBN to predict biochemical relapse following image-guided radiotherapy (IGRT) for intermediate-risk prostate cancer (IR-PCa).. <i>Journal of Clinical Oncology</i> , 2014, 32, 26-26.	1.6	1
118	Comparing characteristics and outcomes of cancer to non-cancer patients admitted to general internal medicine (GIM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 21-21.	1.6	1
119	Stereotactic ablative radiotherapy with targeted MRI-defined gross tumor dose escalation for prostate cancer: dosimetric feasibility and interfraction robustness. <i>Journal of Radiation Oncology</i> , 2017, 6, 397-404.	0.7	0
120	Quantitative assessment of dynamic <sup>18</sup>F-flumethycholine PET and dynamic contrast enhanced MRI in high risk prostate cancer. <i>British Journal of Radiology</i> , 2019, 92, 20180568.	2.2	0
121	The suggested chemopreventive association of metformin with prostate cancer in diabetic patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 191.e17-191.e24.	1.6	0
122	Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management. <i>European Urology Focus</i> , 2021, 7, 513-521.	3.1	0
123	Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 42-42.	1.6	0
124	Permanent seed brachytherapy for low risk prostate cancer, long term outcome, and urinary toxicity.. <i>Journal of Clinical Oncology</i> , 2017, 35, 66-66.	1.6	0
125	The Use of Virtual Care in Patients with Hematologic Malignancies - a Scoping Review. <i>Blood</i> , 2021, 138, 1933-1933.	1.4	0
126	Virtual Care during the COVID-19 Pandemic Among Patients with Hematologic Malignancies - a Princess Margaret Cancer Centre Experience. <i>Blood</i> , 2021, 138, 838-838.	1.4	0



#	ARTICLE	IF	CITATIONS
127	FACE Value of Patient-Reported Outcomes in Dose-Escalated Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 93-95.	0.8	0
128	Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy. Technical Innovations and Patient Support in Radiation Oncology, 2022, 21, 64-70.	1.9	0
129	The prognostic value of urinary cytology after trimodal therapy (TMT) for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0